Published in Int J Cancer on April 10, 1995
Heterogeneity of breast cancer associations with five susceptibility loci by clinical and pathological characteristics. PLoS Genet (2008) 6.22
Tyrosine phosphorylation inhibits PKM2 to promote the Warburg effect and tumor growth. Sci Signal (2009) 5.57
FGFR2 variants and breast cancer risk: fine-scale mapping using African American studies and analysis of chromatin conformation. Hum Mol Genet (2009) 2.62
Tyrosine phosphorylation of mitochondrial pyruvate dehydrogenase kinase 1 is important for cancer metabolism. Mol Cell (2011) 2.61
Pleiotropic effects of FGFR1 on cell proliferation, survival, and migration in a 3D mammary epithelial cell model. J Cell Biol (2005) 1.81
Inducible dimerization of FGFR1: development of a mouse model to analyze progressive transformation of the mammary gland. J Cell Biol (2002) 1.61
Tyrosine phosphorylation of lactate dehydrogenase A is important for NADH/NAD(+) redox homeostasis in cancer cells. Mol Cell Biol (2011) 1.42
Interferon-γ Promotes Inflammation and Development of T-Cell Lymphoma in HTLV-1 bZIP Factor Transgenic Mice. PLoS Pathog (2015) 1.41
Signalling pathways implicated in early mammary gland morphogenesis and breast cancer. PLoS Genet (2006) 1.40
soc-2 encodes a leucine-rich repeat protein implicated in fibroblast growth factor receptor signaling. Proc Natl Acad Sci U S A (1998) 1.39
CCAAT/enhancer-binding protein beta: its role in breast cancer and associations with receptor tyrosine kinases. Expert Rev Mol Med (2009) 1.38
Characterization of fibroblast growth factor receptor 2 overexpression in the human breast cancer cell line SUM-52PE. Breast Cancer Res (2000) 1.23
A Decade of FGF Receptor Research in Bladder Cancer: Past, Present, and Future Challenges. Adv Urol (2012) 1.16
Fibroblast growth factor receptor 1 promotes proliferation and survival via activation of the mitogen-activated protein kinase pathway in bladder cancer. Cancer Res (2009) 1.16
Tyrosine kinase signalling in breast cancer: fibroblast growth factors and their receptors. Breast Cancer Res (2000) 1.16
Allele-specific regulation of FGFR2 expression is cell type-dependent and may increase breast cancer risk through a paracrine stimulus involving FGF10. Breast Cancer Res (2011) 1.09
Fibroblast growth factor 2 in breast cancer: occurrence and prognostic significance. Br J Cancer (1997) 1.07
Genetic variation in the chromosome 17q23 amplicon and breast cancer risk. Cancer Epidemiol Biomarkers Prev (2009) 1.05
Expression profiling of familial breast cancers demonstrates higher expression of FGFR2 in BRCA2-associated tumors. Breast Cancer Res Treat (2008) 1.00
Discovery of novel fibroblast growth factor receptor 1 kinase inhibitors by structure-based virtual screening. J Med Chem (2010) 0.99
Over-expression of fibroblast growth factor receptor 3 in human hepatocellular carcinoma. World J Gastroenterol (2005) 0.97
The POU homeodomain protein OCT3 as a potential transcriptional activator for fibroblast growth factor-4 (FGF-4) in human breast cancer cells. Biochem J (2003) 0.97
Mammary tumorigenesis induced by fibroblast growth factor receptor 1 requires activation of the epidermal growth factor receptor. J Cell Sci (2011) 0.96
Low-risk susceptibility alleles in 40 human breast cancer cell lines. BMC Cancer (2009) 0.94
Rationale for targeting fibroblast growth factor receptor signaling in breast cancer. Breast Cancer Res Treat (2015) 0.93
Fibroblast growth factor receptor 4 (FGFR4): a targetable regulator of drug resistance in colorectal cancer. Cell Death Dis (2014) 0.93
Functional roles of fibroblast growth factor receptors (FGFRs) signaling in human cancers. Apoptosis (2013) 0.89
Fibroblast growth factor receptor 1 activation in mammary tumor cells promotes macrophage recruitment in a CX3CL1-dependent manner. PLoS One (2012) 0.88
Peptide ligand and PEG-mediated long-circulating liposome targeted to FGFR overexpressing tumor in vivo. Int J Nanomedicine (2012) 0.87
FGFR2 protein expression in breast cancer: nuclear localisation and correlation with patient genotype. BMC Res Notes (2011) 0.87
Expression of acidic fibroblast growth factor (aFGF) and fibroblast growth factor receptor 4 (FGFR4) in breast fibroadenomas. J Clin Pathol (2001) 0.87
Expression of keratinocyte growth factor and its receptor in human breast cancer. Br J Cancer (1997) 0.85
A novel isoform of the B cell tyrosine kinase BTK protects breast cancer cells from apoptosis. Genes Chromosomes Cancer (2013) 0.84
The location of acidic fibroblast growth factor in the breast is dependent on the activity of proteases present in breast cancer tissue. Br J Cancer (1997) 0.84
Fibroblast growth factor 8 is expressed at higher levels in lactating human breast and in breast cancer. Br J Cancer (2002) 0.82
The suppression of fibroblast growth factor 2/fibroblast growth factor 4-dependent tumour angiogenesis and growth by the anti-growth factor activity of dextran derivative (CMDB7). Br J Cancer (1998) 0.82
Differential roles of fibroblast growth factor receptors (FGFR) 1, 2 and 3 in the regulation of S115 breast cancer cell growth. PLoS One (2012) 0.81
Matrix-comparative genomic hybridization from multicenter formalin-fixed paraffin-embedded colorectal cancer tissue blocks. BMC Cancer (2007) 0.81
Fibroblast growth factor receptor 4 (FGFR4) and fibroblast growth factor 19 (FGF19) autocrine enhance breast cancer cells survival. Oncotarget (2016) 0.81
Is fibroblast growth factor receptor 4 a suitable target of cancer therapy? Curr Pharm Des (2014) 0.80
Trace elements as tumor biomarkers and prognostic factors in breast cancer: a study through energy dispersive x-ray fluorescence. BMC Res Notes (2012) 0.80
Risk of breast cancer in families with cleft lip and palate. Ann Epidemiol (2011) 0.80
FGF1-gold nanoparticle conjugates targeting FGFR efficiently decrease cell viability upon NIR irradiation. Int J Nanomedicine (2012) 0.79
Inhibition of Metastatic Potential in Breast Carcinoma In Vivo and In Vitro through Targeting VEGFRs and FGFRs. Evid Based Complement Alternat Med (2013) 0.79
Emerging therapeutic targets in metastatic progression: A focus on breast cancer. Pharmacol Ther (2016) 0.79
Fibroblast growth factor receptor 4 polymorphism is associated with liver cirrhosis in hepatocarcinoma. PLoS One (2015) 0.77
Down-regulation of a novel form of fibroblast growth factor receptor 1 in human breast cancer. Br J Cancer (1997) 0.76
RasGAP Shields Akt from Deactivating Phosphatases in Fibroblast Growth Factor Signaling but Loses This Ability Once Cleaved by Caspase-3. J Biol Chem (2015) 0.75
Transitions from mono- to co- to tri-culture uniquely affect gene expression in breast cancer, stromal, and immune compartments. Biomed Microdevices (2016) 0.75
Phage displayed peptides/antibodies recognizing growth factors and their tyrosine kinase receptors as tools for anti-cancer therapeutics. Int J Mol Sci (2012) 0.75
Novel Strategies to Improve the Endocrine Therapy of Breast Cancer. Oncol Rev (2017) 0.75
Receptor specificity of the fibroblast growth factor family. J Biol Chem (1996) 7.58
Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J Natl Cancer Inst (1998) 6.06
Gene expression profiling of breast cell lines identifies potential new basal markers. Oncogene (2006) 4.85
Structure of the Ki-ras gene of the human lung carcinoma cell line Calu-1. Nature (1983) 4.44
Comparative study of the National Cancer Institute and French Federation of Cancer Centers Sarcoma Group grading systems in a population of 410 adult patients with soft tissue sarcoma. J Clin Oncol (1997) 3.60
New human transforming genes detected by a tumorigenicity assay. Mol Cell Biol (1984) 3.43
ERBIN: a basolateral PDZ protein that interacts with the mammalian ERBB2/HER2 receptor. Nat Cell Biol (2000) 2.90
BEK and FLG, two receptors to members of the FGF family, are amplified in subsets of human breast cancers. Oncogene (1991) 2.89
Mutations of ASXL1 gene in myeloproliferative neoplasms. Leukemia (2009) 2.77
Prognostic factors in adult patients with locally controlled soft tissue sarcoma. A study of 546 patients from the French Federation of Cancer Centers Sarcoma Group. J Clin Oncol (1996) 2.53
Histoprognostic grade in BRCA1-associated breast cancer. Lancet (1995) 2.47
Angiogenesis as a prognostic marker in breast carcinoma with conventional adjuvant chemotherapy: a multiparametric and immunohistochemical analysis. J Pathol (1998) 2.40
WNT pathway and mammary carcinogenesis: loss of expression of candidate tumor suppressor gene SFRP1 in most invasive carcinomas except of the medullary type. Oncogene (2001) 2.32
Prognostic factors in localized primary synovial sarcoma: a multicenter study of 128 adult patients. J Clin Oncol (2001) 2.29
Characterization of the HST-related FGF.6 gene, a new member of the fibroblast growth factor gene family. Oncogene (1989) 2.20
Local recurrence after breast-conserving surgery and radiotherapy. Frequency, time course, and prognosis. Cancer (1989) 2.18
Gene expression profiling of primary breast carcinomas using arrays of candidate genes. Hum Mol Genet (2000) 2.15
trkB, a novel tyrosine protein kinase receptor expressed during mouse neural development. EMBO J (1989) 2.14
Characterization of an activated human ros gene. Mol Cell Biol (1986) 1.97
Spectrum of hSNF5/INI1 somatic mutations in human cancer and genotype-phenotype correlations. Hum Mol Genet (1999) 1.96
Prostaglandin in human breast cancer: Evidence suggesting that an elevated prostaglandin production is a marker of high metastatic potential for neoplastic cells. J Natl Cancer Inst (1980) 1.93
Mesenteric panniculitis: review of the leterature and presentation of cases. Surgery (1977) 1.83
A refined molecular taxonomy of breast cancer. Oncogene (2011) 1.78
Mutations of IDH1 and IDH2 genes in early and accelerated phases of myelodysplastic syndromes and MDS/myeloproliferative neoplasms. Leukemia (2010) 1.75
SETBP1 mutations in 658 patients with myelodysplastic syndromes, chronic myelomonocytic leukemia and secondary acute myeloid leukemias. Leukemia (2013) 1.65
Collective nomenclature for LAP proteins. Nat Cell Biol (2000) 1.64
[Reevaluation of indications for adjuvant hormone therapy in primary breast cancer with high metastatic risk]. Bull Cancer (1991) 1.63
The pathology of familial breast cancer: histological features of cancers in families not attributable to mutations in BRCA1 or BRCA2. Clin Cancer Res (2000) 1.62
Medullary carcinoma of the breast. A multicenter study of its diagnostic consistency. Arch Pathol Lab Med (1993) 1.57
Ancient large-scale genome duplications: phylogenetic and linkage analyses shed light on chordate genome evolution. Mol Biol Evol (1998) 1.57
Of worms and men: an evolutionary perspective on the fibroblast growth factor (FGF) and FGF receptor families. J Mol Evol (1997) 1.51
Frequent expression of FAS/APO-1 in Hodgkin's disease and anaplastic large cell lymphomas. Histopathology (1995) 1.51
Causes of inconsistency in diagnosing and classifying intraductal proliferations of the breast. European Commission Working Group on Breast Screening Pathology. Eur J Cancer (2000) 1.50
Detailed map of a region commonly amplified at 11q13-->q14 in human breast carcinoma. Cytogenet Cell Genet (1997) 1.48
Expression profiling: DNA arrays in many guises. Bioessays (1999) 1.45
Mutual exclusion of ASXL1 and NPM1 mutations in a series of acute myeloid leukemias. Leukemia (2009) 1.45
Murine Flt3, a gene encoding a novel tyrosine kinase receptor of the PDGFR/CSF1R family. Oncogene (1991) 1.44
Lobular and ductal carcinomas of the breast have distinct genomic and expression profiles. Oncogene (2008) 1.44
Basal breast cancer: a complex and deadly molecular subtype. Curr Mol Med (2012) 1.43
Cardiotrophin-1 requires LIFRbeta to promote survival of mouse motoneurons purified by a novel technique. J Neurosci Res (1999) 1.42
Expression of the Fgf6 gene is restricted to developing skeletal muscle in the mouse embryo. Development (1993) 1.41
Sensitivity issues in DNA array-based expression measurements and performance of nylon microarrays for small samples. Hum Mol Genet (1999) 1.39
Mutations at BRCA1: the medullary breast carcinoma revisited. Cancer Res (1998) 1.39
Differential expression assay of chromosome arm 8p genes identifies Frizzled-related (FRP1/FRZB) and Fibroblast Growth Factor Receptor 1 (FGFR1) as candidate breast cancer genes. Oncogene (1999) 1.39
Human FLT3/FLK2 receptor tyrosine kinase is expressed at the surface of normal and malignant hematopoietic cells. Leukemia (1996) 1.38
Induction of cutaneous 'graft-versus-host like' reaction by recombinant IL-2 after autologous bone marrow transplantation. Bone Marrow Transplant (1995) 1.38
Molecular analysis of the NPM-ALK rearrangement in Hodgkin's disease. J Pathol (1996) 1.38
FGFRI and PLAT genes and DNA amplification at 8p12 in breast and ovarian cancers. Genes Chromosomes Cancer (1993) 1.37
Expression of the FMS/KIT-like gene FLT3 in human acute leukemias of the myeloid and lymphoid lineages. Blood (1992) 1.37
Why are local recurrences after breast-conserving therapy more frequent in younger patients? J Clin Oncol (1990) 1.34
Estrogen regulation in human breast cancer cells of new downstream gene targets involved in estrogen metabolism, cell proliferation and cell transformation. J Mol Endocrinol (2004) 1.33
Genome-wide search for loss of heterozygosity shows extensive genetic diversity of human breast carcinomas. Cancer Res (1997) 1.33
Human FLT3/FLK2 gene: cDNA cloning and expression in hematopoietic cells. Blood (1993) 1.32
The FLT4 gene encodes a transmembrane tyrosine kinase related to the vascular endothelial growth factor receptor. Oncogene (1993) 1.32
Pathological work-up of sentinel lymph nodes in breast cancer. Review of current data to be considered for the formulation of guidelines. Eur J Cancer (2003) 1.31
Functional and phenotypic characterization of cord blood and bone marrow subsets expressing FLT3 (CD135) receptor tyrosine kinase. Blood (1997) 1.30
MOZ is fused to p300 in an acute monocytic leukemia with t(8;22). Genes Chromosomes Cancer (2000) 1.30
Major improvement in the efficacy of BRCA1 mutation screening using morphoclinical features of breast cancer. Cancer Res (2000) 1.29
Patterns of DNA amplification at band q13 of chromosome 11 in human breast cancer. Genes Chromosomes Cancer (1994) 1.27
Acute myeloid leukaemia with 8p11 (MYST3) rearrangement: an integrated cytologic, cytogenetic and molecular study by the groupe francophone de cytogénétique hématologique. Leukemia (2008) 1.27
Submicrometer intracellular chemical optical fiber sensors. Science (1992) 1.26
Consistency achieved by 23 European pathologists from 12 countries in diagnosing breast disease and reporting prognostic features of carcinomas. European Commission Working Group on Breast Screening Pathology. Virchows Arch (1999) 1.24
Calibration of immunohistochemistry for assessment of HER2 in breast cancer: results of the French multicentre GEFPICS study. Histopathology (2003) 1.23
Postoperative serum proteomic profiles may predict metastatic relapse in high-risk primary breast cancer patients receiving adjuvant chemotherapy. Oncogene (2006) 1.23
Murine FGF-12 and FGF-13: expression in embryonic nervous system, connective tissue and heart. Mech Dev (1997) 1.22
Germ line mutation at BRCA1 affects the histoprognostic grade in hereditary breast cancer. Cancer Res (1996) 1.21
The t(6;8)(q27;p11) translocation in a stem cell myeloproliferative disorder fuses a novel gene, FOP, to fibroblast growth factor receptor 1. Blood (1999) 1.21
Helium-neon laser treatment transforms fibroblasts into myofibroblasts. Am J Pathol (1990) 1.21
Structure and expression of human fibroblast growth factor-10. J Biol Chem (1997) 1.20